Even though the medical relevance from the aforementioned cardiovascular chance factor alterations by tirzepatide will likely be assessed within the planned cardiovascular end result analyze SURPASS-CVOT ( "sort":"scientific-demo","attrs": "textual content":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Eval